#United States #Las Vegas #Breast Cancer #Odyssey Health #BreastCheck™

Odyssey Health, Inc. Expands Its Market with BreastCheck™

Odyssey Health, Inc. has recently announced a significant partnership that positions them at the forefront of breast cancer screening technology. The company, known for its commitment to developing life-saving medical devices, has entered into a definitive sublicense agreement, granting its wholly-owned subsidiary, Odyssey Medical Devices, Inc., exclusive global marketing and distribution rights for the innovative BreastCheck™.

A Game-Changer in Breast Cancer Detection

BreastCheck™ is set to disrupt the breast cancer screening landscape with its unique, non-invasive at-home screening solution. The device delivers results in just 15 minutes, making it a convenient first-line screening tool for early detection of breast abnormalities. While it does not replace traditional mammography procedures, it is designed to complement existing methods, helping to enhance patient engagement and increase the frequency of screenings—a critical factor in successful early intervention.

The global breast cancer screening market is remarkable, estimated to be worth around $26 billion. Given the alarming statistics surrounding breast cancer, such as the forecast of 316,950 invasive cases in the U.S. alone by 2025, the timing for the introduction of BreastCheck™ is crucial and opportunistic. The device aligns with the American Cancer Society's recommendations—addressing a significant need for improved screening methods.

Regulatory Approvals and Market Readiness

BreastCheck™ has already secured regulatory approval from the U.S. Food and Drug Administration (FDA) and relevant authorities in the European Union and the United Kingdom. This extensive approval allows for a broad commercial launch, paving the way for Odyssey Health to penetrate international markets and provide a much-needed service aligned with public health goals.

Odyssey Health's President and CEO, Michael Redmond, emphasized the strategic nature of this agreement: “With the addition of BreastCheck™, we are advancing our strategic transition toward revenue-generating commercial products with recurring revenue potential. We believe this agreement provides a clear pathway to near-term revenue, with commercial sales anticipated to commence in the second half of the year.” His comments underline the company’s ambition to accelerate its growth trajectory in alignment with global health needs.

Understanding BreastCheck™

But what exactly does BreastCheck™ do? The device works by averaging temperatures from three different areas of each breast. By comparing temperatures, it can detect subtle changes that may indicate abnormalities. Users can interpret results almost instantly through the BreastCheck™ mobile application, making follow-up with healthcare providers more straightforward.

Breast cancer remains one of the most prevalent cancers affecting women across the globe, accounting for a staggering portion of cancer-related deaths. The World Health Organization estimated that in 2022 alone, approximately 2.3 million women globally were newly diagnosed with the disease. Fast-forward to 2050, and the number of cases each year is projected to soar to 3.2 million if current trends continue.

Given these concerning statistics, the introduction of effective screening solutions is an urgent public health necessity. By offering a low-cost yet effective monitoring solution, Odyssey Health is contributing significantly to the fight against breast cancer.

Odyssey Health's Vision for the Future

Odyssey Health, Inc. is dedicated to generating life-saving medical solutions. Their mission goes beyond mere profit; it focuses on creating distinctive medical technologies that have the potential to save lives and improve healthcare outcomes. With BreastCheck™, they are not just tapping into a lucrative market; they are also addressing a crucial need for more accessible breast cancer screening methods.

As we look ahead, Odyssey Health's promise to deliver this innovative solution represents a hopeful step toward enhancing early detection and improving patient outcomes in the fight against breast cancer. Investors and stakeholders alike are eager to see how the company will leverage this cutting-edge technology as it shifts towards sustainable revenue generation. Stay tuned for updates as commercial sales of BreastCheck™ are expected to launch later this year!